Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma

Selinexor is an orally bioavailable selective inhibitor of nuclear export that has been demonstrated to have preclinical activity in various cancer types and that is currently in Phase I and II clinical trials for advanced cancers. In this study, we evaluated the effects of selinexor in several prec...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, Robert, Zhang, Yi-Xiang, Czaplinski, Jeffrey T., Anatone, Alex J., Sicinska, Ewa T., Fletcher, Jonathan A., Demetri, George D., Wagner, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941336/
https://www.ncbi.nlm.nih.gov/pubmed/26918731
http://dx.doi.org/10.18632/oncotarget.7667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941336/
https://www.ncbi.nlm.nih.gov/pubmed/26918731
http://dx.doi.org/10.18632/oncotarget.7667

Ejemplares similares